Characteristics of subsequent male patients with BC
| Patient no. . | Age at HL (y) . | HL treatment year . | HL treatment regimen . | Interval between HL and BC (y) . | Type of BC . | Primary treatment for BC . | Follow-up time after BC diagnosis (y) . | Vital status at the end of follow-up . |
|---|---|---|---|---|---|---|---|---|
| 1 | 35 | 1973 | RT: mantle field, inverted-Y and splenic hilum (primary; all fields 40 Gy∗) CT: vinblastine as maintenance therapy for ∼2 years | 23 | Infiltrating ductal carcinoma (C50.9, M8500/3) | Surgery and endocrine therapy | 13 | Alive |
| 2† | 23 | 1982 | CT: 8 cycles of MOPP (primary), 4 cycles of MOPP and 6 cycles of MOPP-ABV (relapse) RT: neck, supraclavicular, infraclavicular, and left axillary fields (relapse; RT dose not available) | 18 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3), TNM-stage IIIA, and ER+/PR+/HER2 equivocal | CT (FAC [5-FU, doxorubicin, and cyclophosphamide]), mastectomy, RT, and endocrine therapy (tamoxifen) | 3 | Deceased (cause of death: BC) |
| 3‡ | 32 | 1978 | CT: 6 cycles of MOPP (primary) RT: Inverted-Y, spleen, and inguinal field (primary; all fields 40 Gy∗) | 32 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3), TNM-stage IIB, and ER+/PR+/HER2– | Endocrine therapy (exemestane, tamoxifen, and anastrozole) | 6 | Deceased (cause of death: BC) |
| 4§ | 28 | 1993 | CT: 6 cycles of MOPP-ABV (primary) RT: mediastinum, supraclavicular, and para-aortic fields (primary; RT dose not available) | 30 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3) | Surgery only | 0 | Alive |
| 5 | 12 | 1991 | CT: 2 cycles of OEPA and 2 cycles of COPP (primary) RT: neck, supraclavicular, infraclavicular, and right axillary fields (primary; RT dose not available) | 27 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IIA, and ER+/PR+/HER2– | CT (AC [doxorubicin/cyclo-phosphamide] and docetaxel), surgery, RT, and endocrine therapy (tamoxifen) | 4 | Alive |
| 6‖,¶ | 38 | 1998 | CT: 6 cycles of MOPP-ABV (primary) RT: mediastinum, neck, left lung, and para-aortic field, and spleen (primary; 20 Gy to the left lung, fields below diaphragm 30 Gy, other fields above diaphragm 40 Gy∗) | 18 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IIA, and ER+/PR+/HER2+ | CT (taxanes), targeted therapy (trastuzumab), surgery, and endocrine therapy (tamoxifen) | 6 | Alive |
| 7∗∗ | 25 | 1994 | RT: mediastinum, neck, supraclavicular, and para-aortic field, and spleen (primary; neck and supraclavicular fields 40 Gy, other fields 36 Gy∗) | 27 | Infiltrating duct carcinoma (C50.4, M8500/3), TNM-stage IA, and ER+/PR+/HER2– | Breast conserving surgery and endocrine therapy (tamoxifen) | 2 | Deceased (cause of death: lung cancer) |
| 8 | 26 | 1979 | RT: mantle field, inverted-Y, and spleen (primary; RT dose not available) CT: 8 cycles of BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) (relapse) | 27 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IA, ER+/PR+/HER2– | Mastectomy only | 7 | Alive |
| Patient no. . | Age at HL (y) . | HL treatment year . | HL treatment regimen . | Interval between HL and BC (y) . | Type of BC . | Primary treatment for BC . | Follow-up time after BC diagnosis (y) . | Vital status at the end of follow-up . |
|---|---|---|---|---|---|---|---|---|
| 1 | 35 | 1973 | RT: mantle field, inverted-Y and splenic hilum (primary; all fields 40 Gy∗) CT: vinblastine as maintenance therapy for ∼2 years | 23 | Infiltrating ductal carcinoma (C50.9, M8500/3) | Surgery and endocrine therapy | 13 | Alive |
| 2† | 23 | 1982 | CT: 8 cycles of MOPP (primary), 4 cycles of MOPP and 6 cycles of MOPP-ABV (relapse) RT: neck, supraclavicular, infraclavicular, and left axillary fields (relapse; RT dose not available) | 18 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3), TNM-stage IIIA, and ER+/PR+/HER2 equivocal | CT (FAC [5-FU, doxorubicin, and cyclophosphamide]), mastectomy, RT, and endocrine therapy (tamoxifen) | 3 | Deceased (cause of death: BC) |
| 3‡ | 32 | 1978 | CT: 6 cycles of MOPP (primary) RT: Inverted-Y, spleen, and inguinal field (primary; all fields 40 Gy∗) | 32 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3), TNM-stage IIB, and ER+/PR+/HER2– | Endocrine therapy (exemestane, tamoxifen, and anastrozole) | 6 | Deceased (cause of death: BC) |
| 4§ | 28 | 1993 | CT: 6 cycles of MOPP-ABV (primary) RT: mediastinum, supraclavicular, and para-aortic fields (primary; RT dose not available) | 30 | Infiltrating duct carcinoma of the left breast (C50.9, M8500/3) | Surgery only | 0 | Alive |
| 5 | 12 | 1991 | CT: 2 cycles of OEPA and 2 cycles of COPP (primary) RT: neck, supraclavicular, infraclavicular, and right axillary fields (primary; RT dose not available) | 27 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IIA, and ER+/PR+/HER2– | CT (AC [doxorubicin/cyclo-phosphamide] and docetaxel), surgery, RT, and endocrine therapy (tamoxifen) | 4 | Alive |
| 6‖,¶ | 38 | 1998 | CT: 6 cycles of MOPP-ABV (primary) RT: mediastinum, neck, left lung, and para-aortic field, and spleen (primary; 20 Gy to the left lung, fields below diaphragm 30 Gy, other fields above diaphragm 40 Gy∗) | 18 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IIA, and ER+/PR+/HER2+ | CT (taxanes), targeted therapy (trastuzumab), surgery, and endocrine therapy (tamoxifen) | 6 | Alive |
| 7∗∗ | 25 | 1994 | RT: mediastinum, neck, supraclavicular, and para-aortic field, and spleen (primary; neck and supraclavicular fields 40 Gy, other fields 36 Gy∗) | 27 | Infiltrating duct carcinoma (C50.4, M8500/3), TNM-stage IA, and ER+/PR+/HER2– | Breast conserving surgery and endocrine therapy (tamoxifen) | 2 | Deceased (cause of death: lung cancer) |
| 8 | 26 | 1979 | RT: mantle field, inverted-Y, and spleen (primary; RT dose not available) CT: 8 cycles of BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) (relapse) | 27 | Infiltrating duct carcinoma of the left breast (C50.1, M8500/3), TNM-stage IA, ER+/PR+/HER2– | Mastectomy only | 7 | Alive |
ABV, doxorubicin, bleomycin, and vinblastine; BCVPP, bleomycin, cyclophosphamide, vinblastine, procarbazine, and prednisone; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; CT, chemotherapy; ER, estrogen receptor; FU, fluorouracil; HER2, human epidermal growth factor receptor 2; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; NOS, not otherwise specified; OEPA, vincristine, etoposide, prednisone, and doxorubicin; PR, progesterone receptor; RT, radiotherapy; TNM, TNM classification of malignant tumors.
Radiotherapy was usually applied in fractions from 1.5 to 2.0 Gy.
Patient developed a malignant tumor of lymphatic tissue NOS in 1999, for which he received chemotherapy.
According to the treating radiation oncologist the BC was estimated to be in the previously irradiated para-aortic and spleen fields.
Patient developed a renal cell carcinoma NOS (C64.9, M8312/3) in 2006, for which he received surgery.
Patient developed a transitional cell, papillary carcinoma in the lateral wall of the bladder (C67.2, M8130/3) in 2017, for which he received surgery and immunotherapy.
Patient developed a basal cell carcinoma of the skin (C44.5, M8090/3) in 2021.
Patient developed an adenocarcinoma of the main bronchus (C34.0, M8140/3) in 2021, for which he received radiotherapy and chemotherapy.